Genetic aspects of prostate cancer

Virchows Archiv

Volumn 432, Issue 5, 1998, Pages 389-406

  Latil, Alain ^a   Lidereau, Rosette ^a,b  

^a CENTRE RENÉ HUGUENIN   (France)

^b INSERM   (France)

Author keywords

Comparative genomic hybridization; Fluorescence in situ hybridization; Loss of heterozygosity; Oncogenes; Prostate cancer; Tumour suppressor gene

Indexed keywords

ANDROGEN; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; SOMATOMEDIN; TELOMERASE; TRANSFORMING GROWTH FACTOR;

CANCER GENETICS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CARCINOGENESIS; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 17Q; CHROMOSOME 18Q; CHROMOSOME ANALYSIS; CHROMOSOME ARM; DNA CONTENT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE THERAPY; GENETIC PREDISPOSITION; HUMAN; MALE; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTO ONCOGENE; REVIEW; SOMATIC MUTATION; TELOMERE; TUMOR SUPPRESSOR GENE; WART VIRUS;

DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTO-ONCOGENES;

EID: 0031783205     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280050183     Document Type: Review

References (235)

1. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-Keller JJ, Lieber MM, Jenkins RB (1994) Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 54:3998-4002
2. Alers JC, Krijtenburg PJ, Vissers KJ, Bosman FT, van der Kwast TH, van Dekken H (1995) Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias. Genes Chromosomes Cancer 12:241-250
3. Alexandrow MG, Moses HL (1995) Transforming growth factor β and cell cycle regulation. Cancer Res 55:1452-1457
4. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M (1992) Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 52:5991-5996
5. Aprikian AG, Sarkis AS, Fair WR, Zhang Z-F, Fuks Z, Cordon-Cardo C (1994) Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 151:1276-1285
6. Aprikian A, Bazinet M, Plante M, Meshref A, Trudel C, Aronson S, Nachabe M, Péloquin F, Déssureault J, Narod S, Bégin L, Elhilali M (1995) Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J Urol 154:404-406
7. Arason A, Barkardòttir RB, Egilsson V (1993) Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Iceland families, and possible relationship to prostatic cancer. Am J Hum Genet 52:711-717
8. Avery A, Standberg MD (1992) Chromosomal abnormalities and related events in prostate cancer. Hum Pathol 23:368-380
9. Bandyk MG, Zhao L, Troncoso P, Pister LL, Palmer JL, von Eschenbach AC, Chung LWK, Liang JC (1994) Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer 9:19-27
10. Bao L, Loda M, Janmey PA, Stewart R, Anand-Apte B, Zetter BR (1997) Thymosin β15: a novel regulator of tumor cell mobility upregulated in metastatic prostate cancer. Nat Med 2:1322
11. Berges RR, Vukanovic J, Epstein JI, Carmichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT (1995) Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1:473-480
12. Berthon P, Dimitrov T, Stower M, Cussenot O, Maitland N (1995) A microdissection approach to detect molecular markers during progression of prostate cancer. Br J Cancer 72:946-951
13. Bérubé NG, Speevak MD, Chevrette M (1994) Suppression of tumorigenicity of human prostate cancer cells by introduction of human chromosome del(12)(q13). Cancer Res 54:3077-3081
14. Berx G, Staes K, van Hengel J, Molemans F, Bussemakers MJG, van Bokhoven A, van Roy F (1995) Cloning and characterization of the human invasion supressor gene E-cadherin (CDH1). Genomics 26:281-289
15. Blackburn EH (1991) Structure and function of telomeres. Nature 350:569-573
16. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee W-H (1990) Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 87:7762-7766
17. Bookstein R, Shew J-Y, Chen P-L, Scully P, Lee W-H (1990) Suppression of tumorigeneicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715
18. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC (1993) p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369-3373
19. Bova GS, Robinson JC, Isaacs WB (1993) Chromosome 17 suppresses tumorigenicity of a human prostate cancer cell line. Proc Am Assoc Cancer Res 34:540-543
20. Boyer J, Umar A, Risinger J, Lipford J, Kane M, Yin S, Barrett J, Kolodner R, Kunkel T (1995) Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 55:6063-6070
21. Brewster SF, Browne S, Brown KW (1994) Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma. J Urol 151: 1073-1077
22. Brooks JD, Bova GS, Isaacs WB (1995) Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 26:35-39
23. Brothman AR, Peehl DM, Patel AM, McNeal JE (1990) Freqency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res 50:3795-3803
24. Brothman AR, Patel AM, Peehl DM, Schellhammer PF (1992) Analysis of prostatic tumor cultures using fluorescence in-situ hybridization (FISH). Cancer Genet Cytogenet 62:180-185
25. Brothman AR, Steele MR, Williams BJ, Jones E, Odelberg S, Albertsen HM, Jorde LB, Rohr LR, Stephenson RA (1995) Loss of chromosome 17 loci in prostate cancer detected by polymerase chain reaction quantitation of allelic markers. Genes Chromosomes Cancer 13:278-284
26. Brown JA, Alcaraz A, Takahashi S, Person DL, Lieber MM, Jenkins RB (1994) Chromosomal aneusomies detected by fluorescent in situ hybridization analysis in clinically localized prostate carcinoma. J Urol 152:1157-1162
27. Buchman EC, Nayak RN, Bushman W (1995) Immunohistochemical staining of ras p21: staining in benign and malignant prostate tissue. J Urol 153:233-237
28. Burney TL, Rockove S, Eiseman JL, Jacobs SC, Kyprianou N (1994) Partial growth suppression of human prostate cancer cells by the krev-1 suppressor gene. Prostate 25:177-188
29. Bussemakers MJG, Van Moorselaar RJA, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M (1992) Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 52:2916-2922
30. Buttyan R, Sawczuc IS, Benson MC, Siegal JD, Olsson CA (1987) Enhanced expression of the c-myc proto-oncogene in high grade human prostate cancers. Prostate 11:327-337
31. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB (1990) Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87:8751-8755
32. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89:3367-3371
33. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH (1994) Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 11:153-162
34. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH (1996) Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091-3102
35. Ching KZ, Ramsey E, Pettigrew N, Cunha RD, Jason M, Dodd JD (1993) Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 126:151-158
36. Coetzee GA, Ross RK (1994) Prostate cancer and the androgen receptor. J Natl Cancer Inst 86:872-873
37. Cohen DW, Simak R, Fair WR, Melamed J, Scher HI, Cordon-Cardo C (1994) Expression of transforming growth factor-α and the epidermal growth factor receptor in human prostate tissues. J Urol 152:2120-2124
38. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R (1993) Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400
39. Cooney KA, Wetzel JC, Consolino CM, Wojno KJ (1996) Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 56:4150-4153
40. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ (1996) Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 56:1142-1145
41. Crundwell MC, Arkell DG, Gearty J, Phillips SMA (1997) Genetic alterations in incidentally diagnosed transitional zone prostate cancer: a seven year follow-up. J Urol 158:1568-1575
42. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, Qian J, Takahashi S, Jenkins RB, Bostwick DG, Thibodeau SN (1996) Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 56:4475-4482
43. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C (1993) Genetic alterations in bladder cancer. Lancet 342: 469-471
44. De Lange T (1994) Activation of telomerase in a human tumor. Proc Natl Acad Sci USA 91:2882-2885
45. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL (1995) M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 11;447-449
46. Dong J-T, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC (1995) KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268:884-886
47. Dong J-T, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT (1996) Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 56:4387-4390
48. Dyson N, Howley PM, Münger K, Harlow E (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937
49. Eastham JA, Hall SJ, Seghal I, Wang J, Timme TL, Yang G, Connel-Crowley L, Elledge SJ, Zhang W-W, Harper JW, Thompson TC (1994) In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151-5155
50. Effert PJ, Frye RA, Neubauer A, Liu ET, Walther PJ (1992) Human papillomavirus types 16 and 18 are not involved in human prostate tumorigenesis: analysis of archival human prostate cancer specimens by differential polymerase chain reaction. J Urol 147:192-196
51. Effert PJ, Neubauer A, Walther PJ, Liu ET (1992) Alterations of the p53 gene are associated with the progression of a human prostate carcinoma. J Urol 147:789-793
52. Egawa S, Uchida T, Suyama K, Wang C, Ohori M, Irie S, Iwamura M Koshiba K (1995) Genomic instability of microsatellite repeats in prostate cancer: Relationship to clinicopathological variables. Cancer Res 55:2418-2421
53. Elo JP, Härkönen AP, Lukkarinen O, Poutanen M, Vihko R, Vihko P (1997) Loss of heterozygosty at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res 57:3356-3359
54. Emmert-Buck M, Vocke C, Pozzatti R, Duray P, Jennings S, Florence C, Zhuang Z, Bostwick D, Liotta L, Linehan W (1995) Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55:2959-2962
55. Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, Barrett JC, Isaacs WB (1997) Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of a-catenin and restoration of E-cadherin function. Cancer Res 55:4813-4817
56. Fan K (1988) Heterogeneous subpopulations of human prostatic adenocarcinoma cells: potential usefulness of p21 protein as a predictor for bone metastasis. J Urol 139:318-322
57. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759-767
58. Fishman JR, Gummerlock PH, Meyers FJ, de Vere White RW (1994) Quantitation of nm23 expression in human prostate tissues. J Urol 152:202-207
59. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston, B, Dodd JG, Matusik RJ (1986) Expression of the c-myc proto- oncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 46:1535-1538
60. Fournier G, Latil A, Amet Y, Ahalain JH, Volant A, Mangin P, Floch HH Lidereau R (1994) Gene amplifications in advanced-stage human prostate cancer. Urol Res 22:343-347
61. Fowler JE, Lau JLT, Ghosh L, Mills SE, Mounzner T (1988) Epidermal growth factor and prostatic carcinoma: an immunohistochemical study. J Urol 139:857-861
62. Fox SB, Persad RA, Coleman N, Day CA, Silcocks PD Collins CC (1994) Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (Tla) prostatic adenocarcinoma. Br J Urol 74:214-220
63. Friend SH, Bernards R, Rogeli S, Weinberg RA, Rapaport JM, Albert DM Dryja TP (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646
64. Fudge K, Wang CY, Stearns NE (1994) Immunocytochemical analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor a and b receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol 7:549-554
65. Fukumoto M, Shevrin DH, Roninson IB (1988) Analysis of gene amplification in human tumor cell line. Proc Natl Acad Sci USA 85:6846-6850
66. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastavu S (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861-2864
67. Gao X, Honn KV, Grignon D, Sakr W, Chen YQ (1993) Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res 53:2723-2727
68. Gao X, Wu N, Grignon D, Zacharek A, Liu H, Salkowski A, Li G, Sakr W, Sarkar F, Porter AT, Chen YQ, Honn KV (1994) High frequency of mutator phenotype in human prostate cancer. Oncogene 9:2999-3003
69. Gao X, Chen Y, Wu N, Grignon D, Sakr W, Porter A, Honn K (1995) Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11:1395-1398
70. Gao X, Porter AT, Grignon DJ, Pontes JE, Honn KV (1997) Diagnostic and prognostic markers for human prostate cancer. Prostate 31:264-281
71. Gao AC, Lou W, Dong J-T, Isaacs JT (1997) CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 57:846-849
72. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcoot J, Hennekens CH, Kantoff PW (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 64:3320-3323
73. Gomez Lahoz E, Xu L, Schreiber-Agus N, DePinho RA (1994) Suppression of myc, but not E1a. transformation activity by max- associated proteins, Mad and Mxil. Proc Natl Acad Sci USA 91:5503-5507
74. Graff J, Herman J, Lapidus R, Chopra H, Xu R, Jarrard D, Isaacs W, Pitha P, Davidson N, Baylin S (1995) E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55:5195-5199
75. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878
76. Gumerlock PH, Poonamalee UR, Meyers FJ, de Vere White RW (1991) Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 51:1632-1637
77. Haldar S, Jena N, Croce C (1995) Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507-4511
78. Hamdy SM, Aprikian AG, Begin LR, Fair WR, Bazinet M (1994) ras p21 overexpression is a late event in prostate cancer. Int J Oncol 4:627-631
79. Hannon GJ, Beach D (1994) p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261
80. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, Srivastava S (1995) Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 154:414-121
81. Hemminki A, Peltomäki P, Mecklin JP, Järvinen H, Salovaara R, Nystrs̈m-Lahti M, de la Chapelle A, Aaltonen LA (1994) Loss of the wild type MLHI gene is a feature of hereditary nonpolyposis colorectal cancer. Nat Genet 8:405-410
82. Henke RP, Krüger E, Ayhan N, Hübner D, Hammerer P (1993) Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kinetic. Virchows Arch [A] 422:61-66
83. Henke RP, Krûger E, Ayhan N, Hûhner D, Hammerer P (1994) Frequency and distribution of numerical chromosomal aberrations in prostatic cancer. Hum Pathol 25:476-484
84. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A (1995) Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55:3068-3072
85. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ (1991) bcl2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961-6965
86. Hsieh JT, Luo W, Song W, Wang Y, Kleinerman DI, Van NT, Lin SH (1995) Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 55:190-197
87. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML (1995) Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147:386-396
88. Ibrahim GK, Kerns BJ, MacDonald JA, Ibrahim SN, Kinney RB. Humphrey PA, Robertson CN (1993) Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J Urol 149:170-173
89. Ichikawa T, Ichikawa Y, Dong J, Hawkins AL, Griffin CA, Isaacs WB, Oshimura M, Barrett JC, Isaacs JT (1992) Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res 52:3486-3490
90. Ichikawa T, Nihei N, Suzuki H, Oshimura M, Emi M, Nakamura Y, Hayata I, Isaacs JT, Shimazaki J (1994) Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. Cancer Res 54:2299-2302
91. Igawa M, Rukstalis DB, Tanabe T, Chodak GW (1994) High levels of nm23 expression are related to cell proliferation in human prostate cancer. Cancer Res 54:1313-1318
92. Isaacs WB, Bova GS, Morton MA, Bussemaker MJG, Brooks JD, Ewing CM (1994) Molecular biology of prostate cancer. Semin Oncol 21:514-521
93. Isaacs WB, Carter BS, Morton MA, Bussemaker MJG, Brooks JD, Ewing CM (1994) Molecular genetics and chromosomal alterations in prostate cancer. Cancer 75:2004-2012
94. Isomura M, Tanigami A, Saito H, Harada Y, Katagiri T, Inazawa J, Ledbetter DH, Nakamura Y (1994) Detailed analysis of loss of heterozygosity on chromosome band 17p13 in breast carcinoma on the basis of a high-resolution physical map with 29 markers. Genes Chromosomes Cancer 9:173-179
95. Ittman M (1996) Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma. Prostate 28:275-281
96. Ittman M, Wieczorek R (1997) Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol 27:28-34
97. Ivanovic V, Melman A, David-Joseph B, Valvic M, Geliebter J (1995) Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat Med 1:282-284
98. Jarrard D, Bussemakers M, Bova G, Isaacs W (1995) Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res 1:1471-1478
99. Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG, Isaacs WB (1997) Deletional, mutational, methylation analyses of CDKN2 (p16/MTSI) in primary and metastatic prostate cancer. Gene Chromosomes Cancer 19:90-96
100. Johansson B, Heim S, Mandahl N, Mertens F, Mitelman F (1993) Trisomy 7 in nonneoplastic cells. Genes Chromosomes Cancer 6:199-205
101. Johansson JE, Andersson SO, Krusemo UB, Adami HO, Bergström R, Kraaz W (1989) Natural history of localised prostate cancer: a population-based study in 223 untreated patients. Lancet I:799-802
102. Jones E, Zhu XL, Rohr LR, Stephenson RA, Brothman AR (1994) Aneusomy of chromosome 7 and 17 detected by FISH in prostate cancer and the effects of selection in vivo. Genes Chromosomes Cancer 11:163-170
103. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocrinol Rev 16:3-34
104. Joos S, Bergerheim USR, Pan Y, Matsuyama H, Bentz M, du Manoir S, Lichter P (1995) Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chromosomes Cancer 14:267-276
105. Kagan J, Stein J, Babaian RJ, Joe Y-S, Pister LL, Glassman AB, von Eschenbach AC, Troncoso P (1995) Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as sites for candidate tumor suppressor genes. Oncogene 11:2121-2126
106. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D (1992) Comparative genomic hydridization for molecular cytogenetic analysis of solid tumors. Science 258:818-822
107. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE, Skolnick MH (1994) A cell cycle regular potentially involved in genesis of many tumor types. Science 264:436-440
108. Keetch DW, Rice JP, Suarez BK, Catalona WJ (1995) Familial aspects of prostate cancer: a case control study. J Urol 154:2100-2102
109. Kim IY, Kim JH, Zelner DJ, Ahn HJ, Sensibar JA, Lee C (1996) Transforming growth factor-β1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer line, LNCaP. Endocrinology 137:991-999
110. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kalo M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C (1996) Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 2:1255-1261
111. Kim MW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Wienrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2014
112. Klingelhutz A, Hedrick L, Cho K, McDougall J (1995) The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene 10:1581-1586
113. Knudson AG (1993) Antioncogenes and human cancer. Proc Natl Acad Sci USA 90:10914-10921
114. Komiya A, Suzuki H, Aida S, Yatani R, Shimazaki J (1995) Mutational analysis of CDKN2 (CDK41/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 86:622-625
115. Komiya A, Suzuki H, Ueda T, Yatani R, Emi M, Ito H, Shimazaki J (1996) Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer. Genes Chromosomes Cancer 17:245-253
116. Konishi N, Enomoto T, Ohshima M, Ward JM, Rice JM (1992) K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 69:2293-2299
117. Konishi N, Nakaoka S, Tsuzuki T, Matsumoto K, Kitahori Y, Hiasa Y, Urano T, Shiku H (1993) Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma. Jpn J Cancer Res 84:1050-1054
118. Konishi N, Hiasa Y, Tsuzuki T, Tao M, Enomoto T, Miller G.J (1997) Comparaison of ras activation in prostate carcinoma in Japanese and American men. Prostate 30:53-57
119. Kovisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi O-P (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314-319
120. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC (1996) Immunohistochemical analysis of bcl-2. bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148:1567-1576
121. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA (1989) Isolation and caracterisation of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subjet of human mammary tumors. Proc Natl Acad Sci USA 86:9193-9197
122. Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoyo H, Iwasaki Y, Kitamura H, Shuin T (1995) Retinoblastoma gene mutations in primary human prostate cancer. Prostate 27: 314-320
123. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul J (1993) Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 150:1427-1433
124. Kunimi K, Bergerheim U, Larsson I-L, Ekman P, Collins VP (1991) Allelotyping of human prostatic adenocarcinoma. Genomics 11:530-536
125. Kyprianou N, English HF, Isaacs JT (1990) Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748-3753
126. Lacombe L, Orlow I, Reuter VE, Fair WR, Dalbagni G, Zhang Z-F, Cordon-Cardo C (1996) Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. Int J Cancer 69:110-113
127. Latil A, Baron J-C, Cussenot O, Fournier G, Boccon-Gibod L, Le Due A, Lidereau R (1994) Oncogene amplifications in early-stage human prostate carcinomas. Int J Cancer 59:637-638
128. Latil A, Baron J-C, Cussenot O, Fournier G, Soussi T, Boccon-Gibod L, Le Duc A, Rou'ssé J, Lidereau R (1994) Genetic alterations in localized prostate cancer identification of a common region of deletion on chromosome arm 18q. Genes Chromosomes Cancer 11:119-125
129. Latil A, Cussenot O, Fournier G, Baron J-C, Lidereau R (1995) Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. Clin Cancer Res 1:1385-1389
130. Latil A, Fournier G, Cussenot O, Lidereau R (1996) Differential chromosome allelic imbalance in the progression of human prostate cancer. J Urol 156:2079-2083
131. Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R (1997) Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Cancer Res 57:1058-1061
132. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EYHP (1987) Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235: 1394-1399
133. Leung HY, Dickson C, Robson CN, Neal DE (1996) Over-expression of fibroblast growth factor-8 in human prostate cancer Oncogene 12:1833-1835
134. Leung HY, Mehta P, Gray L.B, Collins AT, Robson CN, Neal DE (1997) Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene 15:1115-1120
135. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Pue J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella B.C, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947
136. Limon J, Lundgren R, Elfving P., Heim S, Kristoffersson U, Mandahl N, Mitelman F (1989) Double minutes in two primary adenocarcinomas of prostate. Cancer Genet Cytogenet 39:191-194
137. Limonta P, Montagnani Marelli M, Moretti RM, Mott M (1994) Autocrine growth regulation of human prostatic cancer cells: role of EGF/TGFα system. Front Endocrinol 9:285-288
138. Lin Y, Uemura H, Fujinami K, Hosaka M, Harada M, Kubota Y (1997) Telomerase activity in primary prostate cancer. J Urol 157:1161-1165
139. Loeb LA (1994) Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 54:5059-5063
140. Lothe RA, Peltomäki P, Meling GI, Aaltonen LA, Nyström-Lahti M, Pylkkänen L, Heimdal K, Andersen TI, Moller P, Rognum TO, Fossa SD, Haldorsen T, Langmark F, Brogger A, de la Chapelle A, Borresen AL (1993) Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53:5849-5852
141. Lundgren R, Mandah N, Heim S, Limon J, Henrikson H, Mitelman F (1992) Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chromosomes Cancer 4:16-24
142. Macoska JA, Powell IJ, Sakr W, Lane MA (1992) Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate. J Urol 147:1142-1146
143. Mangold KA, Takahashi H, Brandigi C, Wada T, Wakui S, Furusato M, Boyd J, Chandler FW, Allsbrook WC (1997) p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan. J Urol 157:1117-1120
144. Maygarden SJ, Strom S, Ware JL (1992) Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia. Arch Pathol Lab Med 116:269-273
145. McDonald A, Chisholm GD, Habib FK (1990) Production and response of a human prostatic cancer line to transforming growth factor-like molecules. Br J Cancer 62:579-584
146. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J-T, Tu S-M, Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944
147. McGrogan D, Saint-André JP, Dicou E (1992) Expression of nerve growth factor and nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. J Neurochem 59:1381-1391
148. McGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R (1996) Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22 Genomics 35:55-65
149. Mclndoe RA, Stanford JL, Gibbs M, Jarvik GP, Brandzel S, Neal CL, Li S, Gammack JT, Gay AA, Goode EL, Hood L, Ostrander EA (1997) Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet 61:347-353
150. McNicol PJ, Dodd JG (1991) High prevalence of human papillomavirus in prostate tissues. J Urol 145:850-853
151. Micale MA, Mohamed A, Sakr W, Powell IJ, Wolman S (1992) Cytogenetics of primary prostatic adenocarcinoma. Clonality and chromosome instability. Cancer Genet Cytogenet 61:165-173
152. Monroe KR, Yu MC, Kolonel MN, Coetzee GA, Wilkens LR, Ross R.K, Henderson BE (1995) Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med 1:827-829
153. Morton DM, Barrack ER (1995) Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55:2596-2602
154. Morton RA, Ewing CM, Nagafuchi A, Tsukita S and Isaacs WB (1993) Reduction of E-cadherin levels and delation of the α-catenin gene in human prostate cancer cells. Cancer Res 53:3585-3590
155. Morton RA, Watkins JJ, Bova GS, Wales MM, Baylin SB, Isaacs WB (1996) Hypermethylation of chromosome 17p locus D17S5 in human prostate tissue. J Urol 156:512-516
156. Moul JW, Friedrichs PA, Lance RS, Theune SM, Chang EH (1992) Infrequent Ras oncogene mutations in human prostate cancer. Prostate 20:327-338
157. Moyret-Lalle C, Marçais C, Jacquemin J, Moles P, Dvaer A, Soret J-Y, Jeanteur P, Osturk M, Theillet C (1995) ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 64:124-129
158. Murakami Y, Brothman A, Leach R, White R (1995) Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q. Cancer Res 55:3389-3394
159. Nag A, Smith RG (1989) Amplification, rearrangement, and elevated expression of c-myc in the human prostatic carcinoma cell line LNCaP. Prostate 15:115-122
160. Nihei N, Ichikawa T, Kawana Y, Kuramochi H, Kugoh H, Ochimura M, Hayata I, Shimazaki J, Ito H (1996) Mapping of metastasis suppressor gene(s) for rat prostate cancer on the short arm of human chromosome 8 by irradiated microcell-mediated chromosome transfer. Genes Chromosomes Cancer 17:260-268
161. Nihei N, Ichikawa T, Kawana Y, Kuramochi H, Kugoh H, Ochimura M, Killary AM, Rinker-Schaeffer CW, Barett JC, Isaacs JT, Shimazaki J (1995) Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10. Genes Chromosomes Cancer 14:112-119
162. Noordzij MA, van Steenbrugge G-J, Verkaik NS, Schröder FH, van der Kwast TH (1997) The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res 3:805-815
163. Papandreou C, Bogenrieder T, Loganzo F, Felsen D, Scher HI, Chao M, Albino AP, Nanus DM (1994) Alterations in the low-affinity nerve growth factor receptor p75 in prostate cancer cell lines. Proc Am Assoc Cancer Res 35:272
164. Park DJ, Wilczynski SP, Pham EY, Miller CW, Koeffler HP (1997) Molecular analysis of the INK4 family genes in prostate carcinomas. J Urol 157:1995-1999
165. Pflug BR, Onoda M, Lynch JH, Djakiew D (1992) Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human human prostate tissue and loss of expression in four human metastic prostate tumor cell lines. Cancer Res 52:5403-5406
166. Phillips MEA, Ferro MA, Smith PJB, Davies P (1987) Intranuclear androgen receptor deployement and proto-oncogene expression in human diseased prostate. Urol Int 42:115-119
167. Phillips SMA, Barton CM, Lee SJ, Morton DG, Wallace DMA, Lemoine NR, Neoptolemos JP (1994) Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 70:1252-1257
168. Pieretti M, Powell D, Gallion H, Conway P, Case E, Turker M (1995) Hypermethylation at a chromosome 17 "hot spot" is a common event in ovarian cancer. Hum Pathol 26:398-401
169. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LWK (1995) c-MET proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154:293-298
170. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M (1993) Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90:1746-1750
171. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A (1994) p27 (Kip1), a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8:9-22
172. Postel EH, Berberich SJ, Flint SJ, Ferrone CA (1993) Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis. Science 261:478-480
173. Qian J, Bostwick D, Takahashi S, Borell T, Herath J, Lieber M, Jenkins R (1995) Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55:5408-5414
174. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438-4445
175. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. (mini reviews on cellular mechanisms of disease series). J Cell Biol 124:1-6
176. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK (1995) Genetic variability of human SRD5A2 gene: implications for prostate cancer risk. Cancer Res 55:3973-3975
177. Richmond PJM, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M (1997) Aberrant E-cadherin and aα-catenin expression in prostate cancer correlation with patient survival. Cancer Res 57:3189-3193
178. Rinker-Schaeffer CW, Hawkins AL, Ru N, Dong J, Stoica G, Griffin CA, Ichikawa T, Barrett JC, Isaacs JT (1994) Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res 54:6249-6256
179. Rodriguez E, Sreekantaiah C, Chaganti R.S.K (1994) Genetic chances in epithelial solid neoplasia. Cancer Res 54:3398-3406
180. Ruizeveld de Winter JA, Janssen P, Sleddens H, Verleun-Mooijman M, Trapman J, Brinkmann A, Santerse A, Schröder F, van der Kwast T (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144:735-746
181. Sanchez Y, Lovell M, Marin MC, Wong PE, Wolf-Ledbetter ME, McDonnell TJ, McNeil Killary A (1996) Tumor suppression and apoptosis of human prostae carcinoma mediated by a genetic locus within human chromosome 10pter-q11. Proc Natl Acad Sci USA 93:2551-2556
182. Sarkar FH, Sakr WA, Li YW, Sreepathi P, Crissman JD (1993) Detection of human papillomavirus (HPV) DNA in human prostatic tissues by polymerase chain reaction (PCR). Prostate 22:171-180
183. Scher H, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C (1995) Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms. Clin Cancer Res 1:545-550
184. Shackney SE, Smith CA, Miller BW, Burholt DR, Murtha K, Giles HR, Ketterer DM, Pollice AA (1989) Model for the genetic evolution of human solid tumors. Cancer Res 49:3344-3354
185. Shen R, Su ZZ, Olsson CA, Fisher PB (1995) Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc Natl Acad Sci USA 92:6778-6782
186. Sibilia M, Wagner E (1995) Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269:234-238
187. Siegall CB, Schawab G, Nordan RP, Fitzgerald DJ, Pastan I (1990) Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 50:7786-7788
188. Siegsmund MJ, Yamazaki H, Pastan I (1994) Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol 151:1396-1399
189. Sitaras NM, Sariban E, Bravo M, Panatazis P, Antoniades HN (1988) Constitutive production of plateled-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res 48:1930-1935
190. Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber J-E, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB (1997) Major susceptibillity locus for prostate cancer on chromosome I suggested by a genome-wide search. Science 274:1371-1374
191. Smith R, Litwin M, Lu Y, Zetter B (1995) Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Nat Med 1:1040-1045
192. Sommerfeld H-J, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS (1996) Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 56:218-222
193. Stapleton AMF, Timme TL, Gousse EA, Li Q-F, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino PT, Thompson TC (1997) Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 3:1389-1397
194. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF, Tavtigian SV (1997) Identification of a candidate tumour suppressor gene. MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362
195. Steiner MS (1995) Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol 153:1085-1096
196. Sumiya H, Masai M, Akimoto S, Yatani R, Shimazaki J (1990) Histochemical examination of expression of ras p21 protein and R1881-binding protein in human prostatic cancers. Eur J Cancer 26:786-789
197. Sun S, Norad S, Aprikian A, Ghadirian P, Labrie F (1995) Androgen receptor and familial prostate cancer. Nat Med 1:848-849
198. Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R, Shimazaki J (1996) Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer 17:225-233
199. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB (1994) Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 54:3574-3579
200. Tamini Y, Bringuier PP, Smit F, van Bockoven A, Debruyne FMJ, Schalken JA (1996) p16 mutations/deletions are not frequent events in prostate cancer. Br J Cancer 74:120-122
201. Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 21:1393-1398
202. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA (1996) Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 56:4108-4110
203. Terrell RB, Wille AH, Cheville JC, Nystuen AM, Cohen MB, Sheffield VC (1995) Microsatellite instability in adenocarcinoma of the prostate. Am J Pathol 147:799-805
204. Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J, Carr TW, Neal DE (1993) p53 expression and clinical outcome in prostate cancer. Br J Urol 72:778-781
205. Threadgill D, Dlugosz A, Hansen L, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris R, Barnard J, Yuspa S, Coffey R, Magnuson T (1995) Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 269:230-233
206. Tilley WD, Buchanan G, Hickey TE, Bentel JM (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer. Clin Cancer Res 2:277-285
207. Tricoli JV, Gummerlock PH, Yao JL, Chi S-G, D'Souza SA, Nestock BR, de Vere White RW, the Cooperative Prostate Network National Cancer Institute (1996) Alteration of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer 15:108-114
208. Trybus TM, Burgess AC, Wojno KJ, Glover TW, Macoska JA (1996) Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res 56:2263-2267
209. Tulinius H, Egilsson V, Òlafsdòttir G.H, Sigvaldason H (1992) Risk of prostate, ovarian and endometrial cancer among relatives of breast cancer patients. Br Med J 305: 855-857
210. Turkeri LN, Sakr WA, Wykes SM, Grignon DJ, Edson Pontes J. Macoska JA (1994) Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and maligant prostate tissue. Prostate 25:199-205
211. Twillie D, Eisenberg MA, Carducci MA, Hsieh WS, Kim WY, Simon JW (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45:542-549
212. Uchida T, Wada C, Wang C, Ishida H, Egawa S, Yokoyama E, Ohtani H Koshiba K (1995) Microsatellite instability in prostate cancer. Oncogene 10:1019-1022
213. Umbas R, Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HFM, Schaafsma HE, Debruyne FMJ, Isaacs WB (1992) Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52:5104-5109
214. Umbas R, Isaacs WB, Bringier PP, Schaafsma HE, Karthaus HFM, Oosterhof GON, Debruyne FMJ, Schalken JA (1994) Decreased E- cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54:3929-3933
215. Van Den Berg C, Guan X-Y, Von Hoff D, Jenkins R, Bittner M, Griffin C, Kallioniemi O, Visakorpi T, McGill J, Herath J, Epstein J, Sarosdy M, Meltzer P, Trent J (1995) DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implication. Clin Cancer Res 1:11-18
216. Viola M.V, Fromovitz F, Oravez S, Deb S, Finkel G, Lundy J, Hand P, Thor A, Scholm J (1986) Expression of ras oncogene p21 in prostate cancer. N Engl J Med 314:133-137
217. Visakorpi T, Kallioniemi O-P, Heikkinen A, Koivula T, Isola J (1992) Small subgroup of aggressive highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887
218. Visakorpi T, Hyytinen E, Kallioniemi A, Isola J, Kallioniemi OP (1994) Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol 145:624-631
219. Visakorpi T, Kallioniemi AH, Syvånen A-C, Hyytinen ER, Karhu R, Tammella T, Isola JJ, Kallioniemi O-P (1995) Genetic changes in primary and reccurent prostate cancer by comparative genomic hybridization. Cancer Res 55:342-347
220. Visakorpi T, Hyytinen ER, Koivisto P, Tanner M, KeinŠnen R, Palmberg C, Palotie A, Tammella T, Kallioniemi O-P (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406
221. Vleminckx K, Vakaet L, Mareel M, Fiers W, Van Roy F (1991) Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66:107-119
222. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM (1996) Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 56:2411-2416
223. Wales M, Biel M, Deiry WE, Nelkin B, Issa J, Cavenee W, Kuerbitz, S, Baylin S (1995) p53 activates expression of HIC-I, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1:570-577
224. Walker GJ, Palmer JM, Walters MK, Hayward NK (1995) A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer 12:134-141
225. Watanabe M, Shiraishi T, Yatani R, Nomura AMY, Stemmermann GN (1994) International comparison on ras gene mutations in latent prostate carcinoma. Int J Cancer 58:174-178
226. Watanabe M, Imai H, Shiraishi T, Shimazaki J, Kotate T, Yatani R (1995) Microsatellite instability in human prostate cancer. Br J Cancer 72:562-564
227. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323-330
228. Werness BA, Levine AJ, Howley PM (1990) Association of human papilloma virus types 16 and 18 E6 proteins with p53. Science 248:76-79
229. Wierner JS, Liu ET, Walther PJ (1992) Oncogenic human papillomavirus type 16 is associated with sqamous cell cancer of the male urethra. Cancer Res 52:5018-5023
230. Williams BJ, Jones E, Zhu XL, Steele MR, Stephenson RA, Rohr R, Brothman AR (1996) Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer. J Urol 155:720-725
231. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor E, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Spurr N, Ponder B, Eeles R, Peto J, Devilee P, Cornelisse C, Lynnch H, Narod S, Lenoir G, Egilsson V, Barkadottir R, Easton D, Bentley D, Futreal P, Ashworth A, Stratton M (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792
232. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL (1992) Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. Mol Endocrinol 6:2123-2128
233. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347
234. Zenklusen JC, Oshimura M, Barrett JC, Conti CJ (1994) Inhibition of tumorigenicity of a murine squamous cell carcinoma (SCC) cell line by a putative tumor suppressor gene on human chromosome 7. Oncogene 9:2817-2825
235. Zhau HE, Wan DS, Zhou J, Miller GJ, Von Eschenbach AC (1992) Expression of c-erbB2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinogen 5:320-327